Y-mAbs Therapeutics, Inc. Contracts & Agreements
44 Contracts & Agreements
- Business Finance (4 contracts)
- Business Operations (1)
- Human Resources (22)
- Intellectual Property (6)
- Real Estate (2)
- Uncategorized (9)
- License Agreement dated September 11, 2024, by and between the Registrant and Princeton 202 Associates Limited Partnership (Filed With SEC on November 8, 2024)
- Lease Agreement dated September 11, 2024, by and between the Registrant and Princeton 202 Associates Limited Partnership (Filed With SEC on November 8, 2024)
- License Agreement, entered into on October 29, 2024 and effective October 23, 2024, by and between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd (Filed With SEC on November 4, 2024)
- Consultancy Agreement, entered into on July 16, 2024, between Investeringsselskabet GH ApS and the Company (Filed With SEC on July 19, 2024)
- Separation Agreement, entered into on July 16, 2024, between Bo Kruse and Y-mAbs Therapeutics A/S (Filed With SEC on July 19, 2024)
- Employment Agreement, entered into on June 28, 2024, between Peter Pfreundschuh and the Company (Filed With SEC on July 1, 2024)
- Amended and Restated Non-Employee Director Compensation Policy, effective April 26, 2024 (Filed With SEC on May 7, 2024)
- Severance Agreement dated March 21, 2024 between Y-mAbs Therapeutics A/S and Steen Lisby (Filed With SEC on May 7, 2024)
- Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 29, 2024)
- Amendment to Employment Agreement for Dr. Vignesh Rajah, effective as of January 1, 2024 (Filed With SEC on February 29, 2024)
- Form of Performance Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan (Filed With SEC on February 29, 2024)
- Amendment, dated August 16, 2023, to Lease Agreement dated January 10, 2018, by and between the Registrant and RXR HB Owner LLC (Filed With SEC on November 13, 2023)
- Employee Confidential Information and Inventions Assignment Agreement, dated October 17, 2023, between Michael Rossi and the Company (Filed With SEC on October 18, 2023)
- Employment Agreement, entered into on October 17, 2023, between Michael Rossi and the Company (Filed With SEC on October 18, 2023)
- Employment Agreement for Ms. Susan Smith, effective as of January 1, 2022 (Filed With SEC on March 30, 2023)
- Non-Employee Director Compensation Policy, adopted on January 17, 2023 (Filed With SEC on March 30, 2023)
- Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 30, 2023)
- Separation Agreement and General Release, effective as of September 22, 2022, between Y-mAbs Therapeutics, Inc. and Claus Juan Mller San Pedro (Filed With SEC on November 7, 2022)
- Form of Stock Option Grant Notice and Stock Option Agreement for directors under the 2018 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on November 7, 2022)
- Form of Retention Bonus Agreement of Y-mAbs Therapeutics A/S (Filed With SEC on August 8, 2022)
- Form of Retention Bonus Agreement of Y-mAbs Therapeutics, Inc (Filed With SEC on August 8, 2022)
- Retention Bonus Agreement, dated May 30, 2022 by and between EVP and Chief Financial Officer, Bo Kruse and Y-mAbs Therapeutics A/S (Filed With SEC on August 8, 2022)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 8, 2022)
- Amendment to Employment Agreement for Dr. Vignesh Rajah, effective as of March 10, 2021 (Filed With SEC on May 9, 2022)
- Employment Agreement for Dr. Vignesh Rajah, effective as of June 2, 2020 (Filed With SEC on May 9, 2022)
- Amendment to Employment Agreement for Dr. Steen Lisby, effective as of June 1, 2020 (Filed With SEC on May 9, 2022)
- Employment Agreement for Dr. Steen Lisby, effective as of August 1, 2017 (Filed With SEC on May 9, 2022)
- Amendment No. 2, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 9, 2022)
- Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2022)
- Amendment No. 1, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 6, 2021)
- Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)
- Asset Purchase Agreement by and between Y-mAbs Therapeutics, Inc. and United Therapeutics Corporation dated December 24, 2020 (Filed With SEC on February 19, 2021)
- Underwriting Agreement, dated February 17, 2021, by and among Y-mAbs Therapeutics, Inc., and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BofA Securities, Inc., as... (Filed With SEC on February 19, 2021)
- License Agreement dated December 17, 2020 between Y-mabs Therapeutics, Inc., and SciClone Pharmaceuticals International Ltd (Filed With SEC on December 22, 2020)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, directors) (Filed With SEC on November 5, 2020)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, employees, consultants and service providers other than directors) (Filed With SEC on November 5, 2020)
- Master Sponsored Research Agreement effective as of October 7, 2020 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on October 8, 2020)
- License Agreement, effective as of April 15, 2020, by and among the Company, Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology (Filed With SEC on April 21, 2020)
- Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)
- Settlement and Assumption and Assignment of MSK License Agreement and Y-mAbs Sublicense Agreement, dated as of December 2, 2019, by and among the Company, MabVax Therapeutics... (Filed With SEC on December 19, 2019)
- Y-mAbs Sublicense Agreement, dated as of June 27, 2018, by and between the Company and MabVax Therapeutics Holdings, Inc (Filed With SEC on December 19, 2019)
- Underwriting Agreement, dated October 29, 2019, by and among the Company and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of... (Filed With SEC on October 31, 2019)
- Amended and Restated Sponsored Research Agreement effective as of September 13, 2019 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on September 19, 2019)
